LaunchPad Medical Wins a $2.5 Million NIH Grant to Improve Cranial Procedures

This Grant will Enable to Company to Complete its Pre-Clinical Research and Make Key Preparations to Start a Clinical Trial

LaunchPad Medical, Inc. announced that it has been awarded a $2.5 million Direct-to-Phase II Small Business Innovation Research (SBIR) grant (1R44NS115386) from the National Institute of Neurological Disorders and Stroke to advance the development of Tetranite®, its bone adhesive biomaterial technology, to improve cranial flap fixation procedures.

LaunchPad Medical notes the clinical use of this product is expected to enhance bone healing, reduce infection rates, and improve the cosmetic outcome of these procedures for patients while eliminating the need for metal fixation hardware.

Brain surgery often involves performing a craniotomy, a procedure by which a portion of the skull is temporarily removed using bone cutting instruments.   A specialized drill cuts the skull allowing the surgeon to circumscribe a “flap” of bone enabling access to the brain.  The process produces a kerf line, or continuous gap between the bone flap and the rest of the skull.  As part of the surgical closure process, the flap is secured into place with cranial plates and screws.  The kerf line is not typically sealed, which may compromise the ability of the flap to integrate with the surrounding bone.  An open kerf line can also leave a pathway for the leakage of cerebrospinal fluid (“CSF”), which increases the overall risk of infection.

“Infection rates in published literature range up to 21%, which can result in meningitis, subdural empyema, or cerebral abscesses,” said Brian Hess, CEO of LaunchPad Medical.  “CSF leaks increase the risk of infection by as much as 13 times and have been reported to almost double the healthcare cost of the original procedure.”

In a prior large animal study consisting of 41 skeletally mature sheep, biomechanical testing was performed to show both the immediate and sustained adhesive strength of Tetranite.  Histological and histomorphometric analysis was also conducted to evidence the osteointegration of the cranial flaps over a two-year period.  The results of this study were recently published in the Journal of Neurosurgery.  Dr. Kevin T. Foley, the lead author of this publication and Professor of Neurosurgery at the University of Tennessee Health Science Center as well as Chairman of the Semmes-Murphey Clinic, said “This research demonstrates the ability of Tetranite to safely and effectively repair cranial defects without the use of conventional hardware.  In fact, the study showed that Tetranite produces a better, stronger bond between a bone flap and the surrounding skull than do plates and screws, with fewer complications.”

“Having worked with this material as part of LaunchPad Medical’s pre-clinical research team, I foresee the use of Tetranite in many surgical applications such as cranial bone flap fixation,” said Eric J. Woodard, Chief of Neurosurgery at the New England Baptist Hospital.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”